Analyse produit facultative
Avec votre autorisation, nous utilisons une analyse limitée et respectueuse de la vie privée pour comprendre les parcours de recherche utiles. Nous n’utilisons ni traceurs publicitaires ni enregistrement de session. Vous pouvez modifier ce choix dans les préférences. Consultez la Politique de confidentialité.
Eastman Chemical Company's published Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $7.2B | |
|---|---|---|
| Revenue (ttm) | 8.9B | |
| Net income (ttm) | 442M | |
| EPS (ttm) | $3.83 | |
| Shares out | 114.3M | |
| P/E (trailing) | 17.4x | |
| P/E (forward) | 9.2x | |
| Dividend | $3.36 (5.07%) | |
| Volume | 944,015 | |
| Beta | 1.08 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $10.48B | $10.58B | $9.21B | $9.38B | $8.75B | -4.4% |
| Gross profit | $2.50B | $2.14B | $2.06B | $2.29B | $1.84B | -7.3% |
| Operating income | $1.27B | $1.16B | $1.10B | $1.29B | $776.0M | -11.7% |
| Net income | $857.0M | $793.0M | $894.0M | $905.0M | $474.0M | -13.8% |
| EPS (diluted) | $6.25 | $6.35 | $7.49 | $7.67 | $4.10 | -10.0% |
| EBITDA | $1.81B | $1.64B | $1.59B | $1.80B | $1.29B | -8.2% |
| R&D | $254.0M | $264.0M | $239.0M | $250.0M | $255.0M | +0.1% |
| SG&A | $795.0M | $726.0M | $727.0M | $736.0M | $658.0M | -4.6% |
Recent company headlines from major financial publishers.
In the upside path, shares reach $91.33 with an estimated probability of 20.0%, offering an implied return of 45.2% from $62.88. This scenario requires global industrial activity to reaccelerate rapidly, lifting volume demand across specialty additives and advanced materials. Simultaneously, the Kingsport circular plastics platform must ramp seamlessly to full nameplate capacity, capturing premium mix pricing from major consumer brands. Disconfirmation would occur if quarterly volume growth stalls or if customer price increases are rolled back under peer competitive pressure by the middle of FY2027.
The modal path projects shares achieving $70.07 with an estimated probability of 55.0%, generating an implied return of 11.4% relative to $62.88. For this path to unfold, management must execute on affirmed structural cost savings programs while operational line-out progress at the Kingsport facility enables orderly volume expansion across FY2026 and FY2027. This path would be disconfirmed if operating margins fail to expand above cyclical trough levels or if customer destocking in chemical intermediates persists past the conclusion of FY2026.
| Ke ↓ / g → | 1.5% | 1.8% | 2.0% | 2.3% | 2.5% |
|---|---|---|---|---|---|
| 8.6% | $74.3 | $75.4 | $76.6 | $77.9 | $79.3 |
| 9.1% | $71.2 | $72.1 | $73.1 | $74.2 | $75.4 |
| 9.6% | $68.4 | $69.2 | $70.1 | $71.0 | $72.0 |
| 10.1% | $65.9 | $66.6 | $67.3 | $68.2 | $69.0 |
| 10.6% | $63.6 | $64.2 | $64.9 | $65.6 | $66.3 |
Upcoming earnings date and setup when available.
La notation portée par l'édition de recherche publiée chaque mois. Une notation compare le cours à la date d'analyse à la juste valeur ; elle n'indique pas si l'appréciation s'est révélée juste.
| Année | janv. | févr. | mars | avr. | mai | juin | juil. | août | sept. | oct. | nov. | déc. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
